What happened
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) said Chief Executive Officer and director Jon Congleton sold 75,000 shares on 2026-09-30. The Form 4 says the shares changed hands at a weighted-average $25.46 each in multiple transactions. Those sales ranged from $25.00 to $25.82 a share. The transaction totaled about $1.91 million.
Afterward, Congleton still held 528,621 shares of common stock. The filing says the trade was made under a Rule 10b5-1 trading plan adopted on December 23, 2025. Table I also shows the sale code as S, the filing's code for a disposal of common stock. Congleton's post-sale ownership is shown as direct, not indirect, in the ownership column. The form was filed on 2026-10-02.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 75,000 shares | SEC Form 4 | |
| Weighted-average sale price | $25.46 | SEC Form 4 | |
| Sale value | about $1.91 million | SEC Form 4 | |
| Shares held after the sale | 528,621 shares | SEC Form 4 | |
| Sale as share of pre-sale holding | 12.4% | Calculated from SEC Form 4 |
Why it matters
OptimistFi's case is that Mineralys depends on financing its aldosterone-focused development work without dilution overwhelming shareholders. This filing is mixed for that view because Congleton reduced his position, but the sale was preplanned rather than a new discretionary decision. The 75,000 shares were about 12.4% of Congleton's holding before the sale. That makes the disposal material in size even though Congleton remained a large holder afterward.
The sale still leaves Congleton with a large stake, so the filing is a trim rather than an exit. The strongest caveat is the Rule 10b5-1 plan, which can turn a sale into a standing program rather than a fresh statement on the company. The weighted-average price also shows the shares were spread across several trades instead of a single block.
Browse: stock research on every company OptimistFi covers
What's next
Mineralys Therapeutics, Inc.'s next quarterly report is the next scheduled update on file. If later reports or forms show another reduction, the signal from this filing would weaken. If Congleton's ownership stays near 528,621 shares, the filing reads more like a planned trim than a broader change. Until then, the Form 4 shows that Congleton still holds a sizable stake after the sale. That makes this filing a clean snapshot of one preplanned sale.
More from OptimistFi
- MLYS stock: the Mineralys Therapeutics thesis, its status and the next test to watch
- Century Therapeutics, Inc. (NASDAQ: IPSC) Adds Two CNTY-813 Batches
- Applied Digital Corporation (NASDAQ: APLD) Brings 250 MW Online
- ON Semiconductor Corporation (NASDAQ: ON) Cuts Its Deal Cost by 19%
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC Form 4 — Form 4 for Jon Congleton filed on 2026-10-02
Read the full OptimistFi thesis on Mineralys Therapeutics, Inc.: https://optimistfi.com/stocks/MLYS
See what would break the Mineralys Therapeutics, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Mineralys Therapeutics, Inc. investment case, its status and the next test to watch live on the Mineralys Therapeutics, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
